Cite
APA Citation
Godet, S., Protin, C., Dupuis, J., Dartigeas, C., Bastie, J., Herbaux, C., Leblond, V., de Guibert, S., Ghez, D., Brion, A., Ysebaert, L., Delmer, A., & Quinquenel, A. (n.d.). outcome of chronic lymphocytic leukemia patients who switched from either ibrutinib or idelalisib to alternate kinase inhibitor: A retrospective study of the French innovative leukemia organization (FILO). American journal of hematology, 93(2), E52–E54. http://access.bl.uk/ark:/81055/vdc_100055537471.0x00004b